{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:59:34Z","timestamp":1780984774099,"version":"3.54.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100018731","name":"Jiangsu Hengrui Pharmaceuticals Co, Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018731","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10067-026-08085-z","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T18:41:23Z","timestamp":1775068883000},"page":"3111-3119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of ivarmacitinib on patient-reported outcomes in patients with moderate-to-severe active rheumatoid arthritis: a post-hoc analysis of a phase III trial"],"prefix":"10.1007","volume":"45","author":[{"given":"Nannan","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijuan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6899-0141","authenticated-orcid":false,"given":"Lei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixue","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"issue":"10416","key":"8085_CR1","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/s0140-6736(23)01525-8","volume":"402","author":"A Di Matteo","year":"2023","unstructured":"Di Matteo A, Bathon JM, Emery P (2023) Rheumatoid arthritis. Lancet 402(10416):2019\u20132033. https:\/\/doi.org\/10.1016\/s0140-6736(23)01525-8","journal-title":"Lancet"},{"issue":"10","key":"8085_CR2","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41584-022-00827-y","volume":"18","author":"A Finckh","year":"2022","unstructured":"Finckh A, Gilbert B, Hodkinson B et al (2022) Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol 18(10):591\u2013602. https:\/\/doi.org\/10.1038\/s41584-022-00827-y","journal-title":"Nat Rev Rheumatol"},{"key":"8085_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cells10112857","author":"AF Radu","year":"2021","unstructured":"Radu AF, Bungau SG (2021) Management of Rheumatoid Arthritis: An Overview. Cells. https:\/\/doi.org\/10.3390\/cells10112857","journal-title":"Cells"},{"issue":"6","key":"8085_CR4","doi-asserted-by":"publisher","first-page":"e351","DOI":"10.1016\/s2665-9913(23)00094-2","volume":"5","author":"PC Taylor","year":"2023","unstructured":"Taylor PC (2023) Pain in the joints and beyond; the challenge of rheumatoid arthritis. Lancet Rheumatol 5(6):e351\u2013e360. https:\/\/doi.org\/10.1016\/s2665-9913(23)00094-2","journal-title":"Lancet Rheumatol"},{"issue":"5","key":"8085_CR5","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1093\/rheumatology\/keac584","volume":"62","author":"M Dey","year":"2023","unstructured":"Dey M, Nagy G, Nikiphorou E (2023) Comorbidities and extra-articular manifestations in difficult-to-treat rheumatoid arthritis: different sides of the same coin? Rheumatology (Oxford) 62(5):1773\u20131779. https:\/\/doi.org\/10.1093\/rheumatology\/keac584","journal-title":"Rheumatology (Oxford)"},{"key":"8085_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003350","author":"EJF Santos","year":"2023","unstructured":"Santos EJF, Farisogullari B, Dures E et al (2023) Efficacy of non-pharmacological interventions: a systematic review informing the 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2023-003350","journal-title":"RMD Open"},{"issue":"12","key":"8085_CR7","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/s41584-023-01037-w","volume":"19","author":"J Brock","year":"2023","unstructured":"Brock J, Basu N, Schlachetzki JCM et al (2023) Immune mechanisms of depression in rheumatoid arthritis. Nat Rev Rheumatol 19(12):790\u2013804. https:\/\/doi.org\/10.1038\/s41584-023-01037-w","journal-title":"Nat Rev Rheumatol"},{"key":"8085_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ebiom.2017.07.023","volume":"23","author":"T Yamada","year":"2017","unstructured":"Yamada T, Steinz MM, Kenne E et al (2017) Muscle weakness in rheumatoid arthritis: the role of Ca(2+) and free radical signaling. EBioMedicine 23:12\u201319. https:\/\/doi.org\/10.1016\/j.ebiom.2017.07.023","journal-title":"EBioMedicine"},{"issue":"2","key":"8085_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semarthrit.2014.05.001","volume":"44","author":"F Matcham","year":"2014","unstructured":"Matcham F, Scott IC, Rayner L et al (2014) The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum 44(2):123\u2013130. https:\/\/doi.org\/10.1016\/j.semarthrit.2014.05.001","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"8085_CR10","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.3899\/jrheum.151177","volume":"43","author":"L Kilic","year":"2016","unstructured":"Kilic L, Erden A, Bingham CO et al (2016) The reporting of patient-reported outcomes in studies of patients with rheumatoid arthritis: a systematic review of 250 articles. J Rheumatol 43(7):1300\u20131305. https:\/\/doi.org\/10.3899\/jrheum.151177","journal-title":"J Rheumatol"},{"issue":"2","key":"8085_CR11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/ard.2007.084848","volume":"68","author":"U Kalyoncu","year":"2009","unstructured":"Kalyoncu U, Dougados M, Daur\u00e8s JP et al (2009) Reporting of patient-reported outcomes in recent trials in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 68(2):183\u2013190. https:\/\/doi.org\/10.1136\/ard.2007.084848","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"8085_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/13543784.2023.2199919","volume":"32","author":"S Kubo","year":"2023","unstructured":"Kubo S, Nakayamada S, Tanaka Y (2023) JAK inhibitors for rheumatoid arthritis. Expert Opin Investig Drugs 32(4):333\u2013344. https:\/\/doi.org\/10.1080\/13543784.2023.2199919","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"8085_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41584-023-01062-9","volume":"20","author":"Z Szekanecz","year":"2024","unstructured":"Szekanecz Z, Buch MH, Charles-Schoeman C et al (2024) Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. Nat Rev Rheumatol 20(2):101\u2013115. https:\/\/doi.org\/10.1038\/s41584-023-01062-9","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"8085_CR14","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1177\/10600280221113092","volume":"57","author":"EG Boyce","year":"2023","unstructured":"Boyce EG, Rogan EL, Cl M (2023) Upadacitinib for the Treatment of Rheumatoid Arthritis: An Extensive Review. Ann Pharmacother 57(4):450\u2013462. https:\/\/doi.org\/10.1177\/10600280221113092","journal-title":"Ann Pharmacother"},{"key":"8085_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12134527","author":"PC Taylor","year":"2023","unstructured":"Taylor PC, Laedermann C, Alten R et al (2023) A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience. J Clin Med. https:\/\/doi.org\/10.3390\/jcm12134527","journal-title":"J Clin Med"},{"issue":"6","key":"8085_CR16","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1080\/1744666x.2019.1607298","volume":"15","author":"K Yamaoka","year":"2019","unstructured":"Yamaoka K (2019) Tofacitinib for the treatment of rheumatoid arthritis: an update. Expert Rev Clin Immunol 15(6):577\u2013588. https:\/\/doi.org\/10.1080\/1744666x.2019.1607298","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"8085_CR17","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1136\/ard-2024-226385","volume":"84","author":"J Liu","year":"2025","unstructured":"Liu J, Jiang Y, Zhang S et al (2025) Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial. Ann Rheum Dis 84(2):188\u2013200. https:\/\/doi.org\/10.1136\/ard-2024-226385","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"8085_CR18","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/art.1780350502","volume":"35","author":"MC Hochberg","year":"1992","unstructured":"Hochberg MC, Chang RW, Dwosh I et al (1992) The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 35(5):498\u2013502. https:\/\/doi.org\/10.1002\/art.1780350502","journal-title":"Arthritis Rheum"},{"issue":"9","key":"8085_CR19","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.3899\/jrheum.120964","volume":"40","author":"EC Keystone","year":"2013","unstructured":"Keystone EC, van der Heijde D, Kavanaugh A et al (2013) Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis. J Rheumatol 40(9):1487\u20131497. https:\/\/doi.org\/10.3899\/jrheum.120964","journal-title":"J Rheumatol"},{"issue":"19","key":"8085_CR20","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.2106\/jbjs.O.00030","volume":"97","author":"NC Laucis","year":"2015","unstructured":"Laucis NC, Hays RD, Bhattacharyya T (2015) Scoring the SF-36 in orthopaedics: a brief guide. J Bone Joint Surg Am 97(19):1628\u20131634. https:\/\/doi.org\/10.2106\/jbjs.O.00030","journal-title":"J Bone Joint Surg Am"},{"issue":"6","key":"8085_CR21","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00296-018-4005-5","volume":"38","author":"B Fautrel","year":"2018","unstructured":"Fautrel B, Alten R, Kirkham B et al (2018) Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis. Rheumatol Int 38(6):935\u2013947. https:\/\/doi.org\/10.1007\/s00296-018-4005-5","journal-title":"Rheumatol Int"},{"issue":"7","key":"8085_CR22","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1093\/rheumatology\/keaa770","volume":"60","author":"V Strand","year":"2021","unstructured":"Strand V, Tundia N, Wells A et al (2021) Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY. Rheumatology (Oxford) 60(7):3209\u20133221. https:\/\/doi.org\/10.1093\/rheumatology\/keaa770","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"8085_CR23","doi-asserted-by":"publisher","first-page":"5583","DOI":"10.1093\/rheumatology\/keab158","volume":"60","author":"V Strand","year":"2021","unstructured":"Strand V, Tundia N, Bergman M et al (2021) Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE. Rheumatology (Oxford) 60(12):5583\u20135594. https:\/\/doi.org\/10.1093\/rheumatology\/keab158","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"8085_CR24","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1136\/annrheumdis-2016-209821","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Kremer JM, Gaich CL et al (2017) Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). Ann Rheum Dis 76(4):694\u2013700. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209821","journal-title":"Ann Rheum Dis"},{"key":"8085_CR25","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A et al (2018) Rheumatoid arthritis. Nat Rev Dis Primers 4:18001. https:\/\/doi.org\/10.1038\/nrdp.2018.1","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"8085_CR26","doi-asserted-by":"publisher","first-page":"e5474","DOI":"10.1002\/bmc.5474","volume":"36","author":"LK Ding","year":"2022","unstructured":"Ding LK, Chen Y, Liu MY et al (2022) Quantification of SHR0302 in human plasma by UPLC-MS\/MS and application to a pharmacokinetic study. Biomed Chromatogr 36(11):e5474. https:\/\/doi.org\/10.1002\/bmc.5474","journal-title":"Biomed Chromatogr"},{"issue":"10086","key":"8085_CR27","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1016\/s0140-6736(17)31472-1","volume":"389","author":"IB McInnes","year":"2017","unstructured":"McInnes IB, Schett G (2017) Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet (London, England) 389(10086):2328\u20132337. https:\/\/doi.org\/10.1016\/s0140-6736(17)31472-1","journal-title":"Lancet (London, England)"},{"issue":"2","key":"8085_CR28","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/1756-185x.13244","volume":"21","author":"Z Li","year":"2018","unstructured":"Li Z, An Y, Su H et al (2018) Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: patient-reported outcomes from a phase 3 randomized controlled trial. Int J Rheum Dis 21(2):402\u2013414. https:\/\/doi.org\/10.1111\/1756-185x.13244","journal-title":"Int J Rheum Dis"},{"issue":"5","key":"8085_CR29","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s40744-024-00694-x","volume":"11","author":"A Rubbert-Roth","year":"2024","unstructured":"Rubbert-Roth A, Kato K, Haraoui B et al (2024) Safety and efficacy of upadacitinib in patients with rheumatoid arthritis refractory to biologic DMARDs: results through week 216 from the SELECT-CHOICE study. Rheumatol Ther 11(5):1197\u20131215. https:\/\/doi.org\/10.1007\/s40744-024-00694-x","journal-title":"Rheumatol Ther"},{"issue":"11","key":"8085_CR30","doi-asserted-by":"publisher","first-page":"e70458","DOI":"10.1111\/1756-185x.70458","volume":"28","author":"HB Abac\u0131o\u011flu","year":"2025","unstructured":"Abac\u0131o\u011flu HB, \u00c7olak AF, Yal\u00e7\u0131nkaya B et al (2025) From silicone to synovitis: autoimmune\/inflammatory syndrome induced by adjuvants (ASIA) in Beh\u00e7et\u2019s disease. Int J Rheum Dis 28(11):e70458. https:\/\/doi.org\/10.1111\/1756-185x.70458","journal-title":"Int J Rheum Dis"},{"key":"8085_CR31","doi-asserted-by":"publisher","first-page":"154273","DOI":"10.1016\/j.prp.2022.154273","volume":"241","author":"V Ricci","year":"2023","unstructured":"Ricci V, Ricci C, Tamborrini G et al (2023) From histology to sonography in synovitis: EURO-MUSCULUS\/USPRM approach. Pathol Res Pract 241:154273. https:\/\/doi.org\/10.1016\/j.prp.2022.154273","journal-title":"Pathol Res Pract"},{"key":"8085_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/phm.0000000000002929","author":"HB Abac\u0131o\u011flu","year":"2025","unstructured":"Abac\u0131o\u011flu HB, \u00c7etin A (2025) Advanced ultrasonographic insights into neglected\/occult Achilles tendon rupture in rheumatoid arthritis. Am J Phys Med Rehabil. https:\/\/doi.org\/10.1097\/phm.0000000000002929","journal-title":"Am J Phys Med Rehabil"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08085-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08085-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08085-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:25:31Z","timestamp":1780982731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08085-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["8085"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08085-z","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The study protocol was approved by the Ethics Committee and all participants supplied informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Haixue Dai, Shanshan Yin, and Tan Lu are employees of Jiangsu Hengrui Pharmaceuticals Co, Ltd. All other co-authors declare no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}